pp-234 Solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
Australia
GMP approvals
TGA
Comments
Indication: Neuroendocrine Tumors (NETs) / Clinical stage: Phase 3 (registrational trial, recruitment 2026) / Modality: Biologic - radiopharmaceutical (copper-64 labeled SARTATE) / Mechanism & Target: Somatostatin receptor imaging/therapy / Route & form: IV injection / Differentiation: Copper-based radiopharmaceutical with improved imaging vs standard 68Ga-DOTATATE
Manufacturer #39440
Australia-based clinical-stage radiopharmaceutical company developing next-generation Rx theranostic products for oncology using a proprietary platform. The approach pairs a diagnostic imaging isotope with a matched therapeutic isotope for targeted radiotherapy. Multiple clinical programs are advancing globally.
None